Medtronic (MDT) fundamentals: P/E, valuation, undervalued?
Medtronic · Health Care · ref. ETF XLV · price $89.97
In short — Medtronic trades at 24.1× earnings (P/E), 14.0× forward, with a net margin of 13.2 % and revenue growth of +10 %. Read: Cheap for the growth (P/E 14 for ~18% growth (PEG 0.8)).
Is Medtronic stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$89.97-2.2% over range
Aug 28, 25low $73.75 · high $105.35Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
76% recommend buying · 17 analysts
Valuation : Cheap for the growth — P/E 14 for ~18% growth (PEG 0.8)
Valuation
24.1
P/E (price/earnings)
14.0
Forward P/E
1.32
PEG
2.3
Price/book (P/B)
$115.2B
Market cap
3.73
EPS
Profitability & growth
13.2 %
Net margin
+10 %
Revenue growth
+18 %
Earnings growth
$29.1B
Total debt
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Medtronic's P/E and is the stock undervalued? What's a good P/E?
Medtronic's P/E is 24.1 (forward 14.0). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Medtronic profitable?
Medtronic has a net margin of 13.2 % (EPS 3.73). The company is profitable.
Is MDT stock expensive?
Our read: "Cheap for the growth" — P/E 14 for ~18% growth (PEG 0.8). Cross-check with growth and sector.
💬 A question about Medtronic? The JPI assistant answers using our backtest data.